Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma

被引：0

作者：

Astrid Lièvre

Bérèngere Ouine

Jim Canet

Aurélie Cartier

Yael Amar

Wulfran Cacheux

Odette Mariani

Rosine Guimbaud

Janick Selves

Thierry Lecomte

Serge Guyetant

Ivan Bieche

Frédérique Berger

Leanne de Koning

机构：

[1] CHU Pontchaillou,Service des maladies de l’appareil digestif

[2] Université Rennes 1,Faculté de médecine

[3] Rue Bataille Flandres-Dunkerque,Inserm ER440

[4] Institut Curie,Oncogenesis, Stress and Signaling

[5] PSL Research University,Department of Translational Research

[6] PSL Research University,Institut Curie

[7] Unit of Biostatistics,Department of Medical Oncology, Institut Curie

[8] René Huguenin Hospital,Department of Genetics, Institut Curie

[9] Unit of Pharmacogenomics,Biological Resource Center, Institut Curie

[10] PSL Research University,Centre de Recherche en Cancérologie de Toulouse, Unité Mixte de Recherche

[11] 26 rue d’Ulm,Service d’oncologie médicale

[12] 1037 INSERM—Université Toulouse III,Department of Pathology

[13] Centre Hospitalier Universitaire de Toulouse,Hôpital Trousseau—CHRU de TOURS

[14] Centre Hospitalier Universitaire de Toulouse,UMR CNRS 7292 (GICC)

[15] Service d’Hépato-Gastro-Entérologie,Hôpital Trousseau—CHRU de TOURS

[16] Université François Rabelais,Institut Curie

[17] Service d’Anatomie et Cytologie Pathologiques—Tumorothèque,undefined

[18] PSL Research University,undefined

[19] INSERM U900,undefined

来源：

British Journal of Cancer | 2018年 / 119卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Supplementary Table 1 and the Supplementary Figure legends were not included when this manuscript was first published. The files are now available here.

引用

页码：387 / 387

共 50 条

[31] Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
Kagawa, Yoshinori
Kotani, Daisuke
Bando, Hideaki
Takahashi, Naoki
Hamaguchi, Tetsuya
Kanazawa, Akiyoshi
Kato, Takeshi
Ando, Koji
Satake, Hironaga
Shinozaki, Eiji
Sunakawa, Yu
Takashima, Atsuo
Yamazaki, Kentaro
Yuki, Satoshi
Nakajima, Hiromichi
Nakamura, Yoshiaki
Wakabayashi, Masashi
Taniguchi, Hiroya
Ohta, Takashi
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: A systematic review and metanalysis
Belluomini, L.
Carandina, I.
Bonetti, F.
Urbini, B.
Daniel, F.
Lancia, F.
Martella, L. R.
Toma, I.
Moretti, A.
Banno, E.
Nisi, C.
Da Ros, L.
Frassoldati, A.
ANNALS OF ONCOLOGY, 2017, 28
[33] Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC)
Cremolini, Chiara
Berenato, Rosa
Morano, Federica
Moretto, Roberto
Perrone, Federica
Tamborini, Elena
Rossini, Daniele
Gloghini, Annunziata
Busico, Adele
Fuca, Giovanni
Baratelli, Chiara
Tamburini, Emiliano
Capone, Iolanda
Volpi, Chiara Costanza
Milione, Massimo
Di Maio, Massimo
Fontanini, Gabriella
De Braud, Filippo
Falcone, Alfredo
Pietrantonio, Filippo
CANCER RESEARCH, 2017, 77
[34] Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?
Triest, Lars
Debeuckelaere, C.
Vandamme, T.
Van Den Heuvel, B.
Van Den Brande, J.
Papadimitriou, K.
Rasschaert, M.
Prenen, H.
Peeters, M.
CURRENT COLORECTAL CANCER REPORTS, 2019, 15 (04) : 130 - 134
[35] Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer-PARADIGM Shift
Robinson, Hannah R.
Lieu, Christopher H.
JAMA ONCOLOGY, 2023, 9 (06) : 767 - 769
[36] Predictive value of wild-type EGFR determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
Khelwatty, Said Abdullah
Essapen, Sharadah
Bagwan, Lzhar
Green, Margaret
Seddon, Alan
Modjtahedi, Helmout
CANCER RESEARCH, 2016, 76
[37] Controversies in the treatment of RAS wild-type metastatic colorectal cancer
R. Vera
M. Salgado
M. J. Safont
J. Gallego
E. González
E. Élez
E. Aranda
Clinical and Translational Oncology, 2021, 23 : 827 - 839
[38] Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Vera, R.
Salgado, M.
Safont, M. J.
Gallego, J.
Gonzalez, E.
Elez, E.
Aranda, E.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (04): : 827 - 839
[39] Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: a systematic review and metanalysis regular
Carandina, I.
Belluomini, L.
Bonetti, F.
Urbini, B.
Daniel, F.
Lancia, F.
Martella, L. R.
Toma, I.
Moretti, A.
Banno, E.
Nisi, C.
Da Ros, L.
Frassoldati, A.
ANNALS OF ONCOLOGY, 2017, 28
[40] Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Wang, Chongkai
Sandhu, Jaideep
Fakih, Marwan
ONCOLOGIST, 2022, 27 (02): : 104 - 109

← 1 2 3 4 5 →